Chimeric antigen receptor-modified cells for the treatment of cldn6 expressing cancer
OwnerUgur SAHIN, Petra OEHM +4inventors
InventorsUgur SAHIN, Petra OEHM, Benjamin RENGSTL, Katharina REINHARD, Liane Monika PREUSSNER, Özlem TÜRECI
Life of this patent
Estimating the term…
Abstract
The present disclosure relates to chimeric antigen receptor (CAR) expressing immune effector cells showing highly specific and sensitive recognition of CLDN6 expressing cancer cells as well as a high potential for treating cancer in humans.
Claims87
A method of treating a solid tumor in a human comprising administering to the human immune effector cells expressing a chimeric antigen receptor (CAR) molecule, the CAR molecule comprising:
- i) a CLDN6 antigen binding domain;
- ii) a transmembrane domain;
- and
- iii) an intracellular domain that comprises a 4-1BB costimulatory domain, and a CD3-zeta signaling domain.
The method of any one of the preceding claims, wherein the antigen binding domain is connected to the transmembrane domain by a hinge domain.
A composition or medical preparation comprising between 106 to 109 immune effector cells expressing a chimeric antigen receptor (CAR) molecule, the CAR molecule comprising:
- i) a CLDN6 antigen binding domain;
- ii) a transmembrane domain;
- and
- iii) an intracellular domain that comprises a 4-1BB costimulatory domain, and a CD3-zeta signaling domain.
Dependencies are inferred from the claim text.